Rila Therapeutics, established with technology pioneered by Drs. John He and Kyung Lee at the Icahn School of Medicine at Mount Sinai, is a clinical-stage company dedicated to advancing innovative treatments for fibrosis. Our primary focus is on developing safe and efficacious anti-fibrotic therapies. Leading our efforts is a groundbreaking small molecule allosteric inhibitor designed to target HIPK2 in kidney fibrosis. This program has entered phase 2 clinical trials as of April 2026. The prevalence of renal fibrosis presents a significant, unmet medical need, as it underpins the progression of chronic kidney disease towards end-stage renal failure.